Medortus

Medortus is a clinical-stage biotechnology company focused on the discovery and development of next-generation small molecule therapeutics for metabolic and inflammatory diseases. The company's lead program, MDT-001, is an oral small molecule GLP-1 receptor agonist designed to provide a more convenient alternative to injectable treatments for type 2 diabetes and obesity. Medortus leverages its proprietary drug discovery platform to target G-protein coupled receptors (GPCRs) and other high-value biological pathways. Headquartered in Suzhou, China, the company is led by a team of experienced pharmaceutical industry veterans and backed by prominent venture capital firms. Its pipeline also includes dual agonists and treatments for inflammatory conditions, aiming to address significant unmet medical needs globally.